Hypoxia-sensitive pathways in inflammation-driven fibrosis

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 307, Issue 12, 2014, Pages R1369-R1380

  Manresa, Mario C ^a   Godson, Catherine ^a   Taylor, Cormac T ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Fibrosis; Hypoxia; Inflammation; NF B; Smad

Indexed keywords

OXYGEN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CELL MIGRATION; CHRONIC INFLAMMATION; CROHN DISEASE; FIBROBLAST; FIBROSIS; HEALING IMPAIRMENT; HUMAN; HYPOXIA; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NONHUMAN; OXYGEN CONSUMPTION; PHAGOCYTOSIS; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; WOUND HEALING;

EID: 84919459521     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00349.2014     Document Type: Review

References (146)

1. Agarwal SK. Integrins and cadherins as therapeutic targets in fibrosis. Front Pharmacol 5. 131-131, 2014.
2. Andonegui G, Ni A, Leger C, Kelly MM, Wong JF, Jalloul A, Winston BW. Sequential expression of IGF-IB followed by active TGF1 induces synergistic pulmonary fibroproliferation in vivo. Am J Physiol Lung Cell Mol Physiol 303. L788-L798, 2012.
3. Arsura M, Panta GR, Bilyeu JD, Cavin LG, Sovak MA, Oliver AA, Factor V, Heuchel R, Mercurio F, Thorgeirsson SS, Sonenshein GE. Transient activation of NFB through a TAK1/IKK kinase pathway by Gerber HP, Ferrara N, Johnson RS. HIF-1 is essential for myeloid TGF1 inhibits AP-1/SMAD signaling and apoptosis. implications in liver tumor formation. Oncogene 22. 412-425, 2003.
4. Ask K, Bonniaud P, Maass K, Eickelberg O, Margetts PJ, Warburton D, Groffen J, Gauldie J, Kolb M. Progressive pulmonary fibrosis is mediated by TGFisoform 1 but not TGF3. Int J Biochem Cell Biol 40. 484-495, 2008.
5. Baum CL, Arpey CJ. Normal cutaneous wound healing. Clinical correlation with cellular and molecular events. Dermatol Surg 31. 674-686, 2005.
6. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NFB as the matchmaker. Nat Immunol 12. 715-723, 2011.
7. Beyer C, Zenzmaier C, Palumbo-Zerr K, Mancuso R, Distler A, Dees C, Zerr P, Huang J, Friebe A, Sandner P, Distler O, Schett G, Berger P, Distler J. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF signalling. Clin Exp Rheumatol 32. S15-S16, 2014.
8. Biernacka A, Dobaczewski M, Frangogiannis NG. TGFsignaling in fibrosis. Growth Factors 29. 196-202, 2011.
9. Blouin CC, Page EL, Soucy GM, Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages. Implication of hypoxiainducible factor 1. Blood 103. 1124-1130, 2004.
10. Bodempudi V, Hergert P, Smith K, Xia H, Herrera J, Peterson M, Khalil M, Kahm J, Bitterman PB, Henke CA. miR-210 Promotes IPF fibroblast proliferation in response to hypoxia. Am J Physiol Lung Cell Mol Physiol 307. L283-L294, 2014.
11. Boergeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O’Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C. Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. FASEB J 25. 2967-2979, 2011.
12. Brennan EP, Nolan KA, Boergeson E, Gough OS, McEvoy CM, Docherty NG, Higgins DF, Murphy M, Sadlier DM, Ali-Shah ST, Guiry PJ, Savage DA, Maxwell AP, Martin F, Godson C, Consortium G, Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGF R1. J Am Soc Nephrol 24. 627-637, 2013.
13. Bruning U, Fitzpatrick SF, Frank T, Birtwistle M, Taylor CT, Cheong A. NFB and HIF display synergistic behaviour during hypoxic inflammation. Cell Mol Life Sci 69. 1319-1329, 2012.
14. Caamano J, Hunter CA. NFB family of transcription factors. Central regulators of innate and adaptive immune functions. Clin Microbiol Rev 15. 414-429, 2002.
15. Campbell EL, Bruyninckx WJ, Kelly CJ, Glover LE, McNamee EN, Bowers BE, Bayless AJ, Scully M, Saeedi BJ, Golden-Mason L,Ehrentraut SF, Curtis VF, Burgess A, Garvey JF, Sorensen A, Nemenoff R, Jedlicka P, Taylor CT, Kominsky DJ, Colgan SP. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity 40. 66-77, 2014.
16. Cavadas MAS, Nguyen LK, Cheong A. Hypoxia-inducible factor (HIF) network. insights from mathematical models. Cell Commun Signal 11. 42, 2013.
17. Cavin LG, Romieu-Mourez R, Panta GR, Sun JY, Factor VM, Thorgeirsson SS, Sonenshein GE, Arsura M. Inhibition of CK2 activity by TGF1 promotes I Bprotein stabilization and apoptosis of immortalized hepatocytes. Hepatology 38. 1540-1551, 2003.
18. Chakraborty S, Chopra P, Ambi SV, Dastidar SG, Ray A. Emerging therapeutic interventions for idiopathic pulmonary fibrosis. Expert Opin Invest Drugs 23. 893-910, 2014.
19. Chen LY, Zuraw BL, Zhao M, Liu FT, Huang S, Pan ZXK. Involve-ment of protein tyrosine kinase in Toll-like receptor 4-mediated NFB activation in human peripheral blood monocytes. Am J Physiol Lung Cell Mol Physiol 284. L607-L613, 2003.
20. Chen X, Wang H, Liao HJ, Hu W, Gewin L, Mernaugh G, Zhang S, Zhang ZY, Vega-Montoto L, Vanacore RM, Faessler R, Zent R, Pozzi A. Integrin-mediated type II TGFreceptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling. J Clin Invest 124. 3295-3310, 2014.
21. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 54. 237-241, 2005.
22. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, cell-mediated inflammation. Cell 112. 645-657, 2003.
23. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, Taylor CT. Prolyl hydroxylase-1 negatively regulates I B kinase-, giving insight into hypoxia-induced NFB activity. Proc Natl Acad Sci USA 103. 18154-18159, 2006.
24. Cummins EP, Doherty GA, Taylor CT. Hydroxylases as therapeutic targets in inflammatory bowel disease. Lab Invest 93. 378-383, 2013.
25. Cummins EP, Seeballuck F, Keely S., Mangan NE, Callanan JJ, Fallon PG, Taylor CT. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134. 156-165, 2008.
26. Dendooven A, van Oostrom O, van der Giezen DM, Leeuwis JW, Snijckers C, Joles JA, Robertson EJ, Verhaar MC, Nguyen TQ, Goldschmeding R. Loss of endogenous bone morphogenetic protein-6 aggravates renal fibrosis. Am J Pathol 178. 1069-1079, 2011.
27. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NAB, Picariello L, Cazzola P, Monteleone G, Tonelli F, Corazza GR, MacDonald TT, Pender SL. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures. Gut 58. 777-789, 2009.
28. Dobaczewski M, Bujak M, Li N, Gonzalez-Quesada C, Mendoza LH, Wang XF, Frangogiannis NG. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 107. 418-U176, 2010.
29. Drawz PE, Rosenberg ME. Slowing progression of chronic kidneydisease. Kidney Int Suppl 3. 372-376, 2013.
30. Fabrizi F, Martin P, Messa P. Hepatitis B and hepatitis C virus and chronic kidney disease. Acta Gastroenterol Belg 73. 465-471, 2010.
31. Factor V, Oliver AL, Panta GR, Thorgeirsson SS, Sonenshein GE, Arsura M. Roles of Akt/PKB and IKK complex in constitutive induction of NFB in hepatocellular carcinomas of transforming growth factor /c-myc transgenic mice. Hepatology 34. 32-41, 2001.
32. Fang Y, Yu X, Liu Y, Kriegel AJ, Heng Y, Xu X, Liang M, Ding X.miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIFactivation. Am J Physiol Renal Physiol 304. F1274-F1282, 2013.
33. Ferguson MWJ, O’Kane S. Scar-free healing. from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc London Ser B-Biol Sci 359. 839-850, 2004.
34. Filep JG, Zouki C, Petasis NA, Hachicha M, Serhan CN. Antiinflammatory actions of lipoxin A4 stable analogs are demonstrable in human whole blood. Modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions. Blood 94. 4132-4142, 1999.
35. Fiocchi C, Lund PK. Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol 300. G677-G683, 2011.
36. Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, Byrne A, O’Connor A, Gallagher WM, Lenihan CR, Garvey JF, Howell K, Fallon PG, Cummins EP, Taylor CT. An intact canonical NFB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol 186. 1091-1096, 2011.
37. Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arabshahi A, Major C, Deng CX, Russo A, Mitchell JB, Roberts AB. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 160. 1057-1068, 2002.
38. Fraisl P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell 16. 167-179, 2009.
39. Frede S, Stockmann C, Freitag P, Fandrey J. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NFB. Biochem J 396. 517-527, 2006.
40. Freudlsperger C, Bian Y, Wise SC, Burnett J, Coupar J, Yang X, Chen Z, Van Waes C. TGFand NFB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene 32. 1549-1559, 2013.
41. Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ. TGFcoordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res 314. 2725-2738, 2008.
42. Goggins BJ, Chaney C, Radford-Smith GL, Horvat JC, Keely S. Hypoxia and integrin-mediated epithelial restitution during mucosal inflammation. Front Immunol 4. 272-272, 2013.
43. Gradel KO, Nielsen H., Schonheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased shortand long-term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology 137. 495-501, 2009.
44. Greenhalgh DG. The role of apoptosis in wound healing. Int J Biochem Cell Biol 30. 1019-1030, 1998.
45. Gu L, Zhu YJ Yang X, Guo ZJ, Xu WB, Tian XL. Effect ofTGF/Smad signaling pathway on lung myofibroblast differentiation. Acta Pharmacol Sin 28. 382-391, 2007.
46. Guo S, DiPietro LA. Factors affecting wound healing. J Dental Res 89. 219-229, 2010.
47. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 453. 314-321, 2008.
48. Hams E, Saunders SP, Cummins EP, O’Connor A, Tambuwala MT, Gallagher WM, Byrne A, Campos-Torres A, Moynagh PM, Jobin C, Taylor CT, Fallon PG. The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells. Shock 36. 295-302, 2011.
49. Hao JM, Ju HS, Zhao SF, Junaid A, Fleur TSL, Dixon IMC. Elevation of expression of Smads 2, 3, and 4, decorin and TGFin the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 31. 667-678, 1999.
50. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117. 3810-3820, 2007.
51. Himmelfarb J, Tuttle KR. New therapies for diabetic kidney disease. N Engl J Med 369. 2549-2550, 2013.
52. Hindryckx P, De Vos M, Jacques P, Ferdinande L, Peeters H, Olievier K, Bogaert S, Brinkman B, Vandenabeele P, Elewaut D, Laukens D. Hydroxylase inhibition abrogates TNF-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. J Immunol 185. 6306-6316, 2010.
53. Hoesel B, Schmid JA. The complexity of NFB signaling in inflammation and cancer. Mol Cancer 12. 86, 2013.
54. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261. 4337-4345, 1986.
55. Inoue K, Naito Y, Takagi T, Hayashi N, Hirai Y, Mizushima K, Horie R, Fukumoto K, Yamada S, Harusato A, Hirata I, Omatsu T, Yoshida N, Uchiyama K, Ishikawa T, Handa O, Konishi H, Wakabayashi N, Yagi N, Ichikawa H, Kokura S, Yoshikawa T. Daikenchuto, a Kampo medicine, regulates intestinal fibrosis associated with decreasing expression of heat shock protein 47 and collagen content in a rat colitis model. Biol Pharm Bull 34. 1659-1665, 2011.
56. Kapitsinou PP, Sano H, Michael M, Kobayashi H, Davidoff O, Bian A, Yao B, Zhang MZ, Harris RC, Duffy KJ, Erickson-Miller CL, Sutton TA, Haase VH. Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. J Clin Invest 124. 2396-2409, 2014.
57. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group. A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370. 2083-2092, 2014.
58. Kretzschmar M, Massague J. SMADs. mediators and regulators of TGFsignaling. Curr Opin Genet Dev 8. 103-111, 1998.
59. Lan HY. Diverse roles of TGF/Smads in renal fibrosis and inflamma-tion. Int J Biol Sci 7. 1056-1067, 2011.
60. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2. 787-795, 2002.
61. Lisy K, Peet DJ. Turn me on. regulating HIF transcriptional activity. Cell Death Differ 15. 642-649, 2008.
62. Liu T, Yu H, Ullenbruch M, Jin H, Ito T, Wu Z, Liu J, Phan SH. The in vivo fibrotic role of FIZZ1 in pulmonary fibrosis. Plos One 9. e88362, 2014.
63. Lota HK, Wells AU. The evolving pharmacotherapy of pulmonary fibrosis. Expert Opin Pharmacother 14. 79-89, 2013.
64. Maderna P, Godson C. Lipoxins. resolutionary road. Br J Pharmacol 158. 947-959, 2009.
65. Martin GEM, Ask K, Gilpin SE, Kolb M, Gauldie J. The transforming growth factor (TGF) family and pulmonary fibrosis. Drug Discov Today 3. 99-103, 2006.
66. Martins V, Valença SS, Farias-Filho FA, Molinaro R, Simões RL, Ferreira TP, e Silva PM, Hogaboam CM, Kunkel SL, Fierro IM, Canetti C, Benjamim CF. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J Immunol 182. 5374-5381, 2009.
67. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 19. 2783-2810, 2005.
68. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Seminars Cell Dev Biol 13. 29-37, 2002.
69. McClain SA, Simon M, Jones E, Nandi A, Gailit JO, Tonnesen MG, Newman D, Clark RAF. Mesenchymal cell activation is the ratelimiting step of granulation tissue induction. Am J Pathol 149. 1257-1270, 1996.
70. McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 162. 1355-1360, 2003.
71. Medina C, Santos-Martinez MJ, Santana A, Cristina Paz-Cabrera M, Johnston MJ, Mourelle M, Salas A, andGuarner F. Transforming growth factortype 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis. J Pathol 224. 461-472, 2011.
72. Medzhitov R, Janeway CA. Innate immunity. Impact on the adaptive immune response. Curr Opin Immunol 9. 4-9, 1997.
73. Metzen E, Ratcliffe PJ. HIF hydroxylation and cellular oxygen sensing. Biol Chem 385. 223-230, 2004.
74. Miyata T, Suzuki N, van Ypersele de Strihou C. Diabetic nephropathy. are there new and potentially promising therapies targeting oxygen biology? Kidney Int 84. 693-702, 2013.
75. Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev 22. 376-381, 2013.
76. Moon JO, Welch TP, Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1-deficient mice. Am J Physiol Gastrointest Liver Physiol 296. G582-G592, 2009.
77. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8. 958-969, 2008.
78. Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGFsignal transduction. J Cell Sci 114. 4359-4369, 2001.
79. Murdoch C, Muthana M, Lewis CE. Hypoxia regulates macrophage functions in inflammation. J Immunol 175. 6257-6263, 2005.
80. Muzio M, Bosisio D, Polentarutti N, D’Amico G, Stoppacciaro A, Mancinelli R, van’t Veer C, Penton-Rol G, Ruco LP, Allavena P, Mantovani A. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes. Selective expression of TLR3 in dendritic cells. J Immunol 164. 5998-6004, 2000.
81. Myllyharju J. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. Ann Med 40. 402-417, 2008.
82. Nathan C. Immunology— oxygen and the inflammatory cell. Nature 422. 675-676, 2003.
83. Nguyen LK, Cavadas MAS, Scholz CC, Fitzpatrick SF, Bruning U, Cummins EP, Tambuwala MM, Manresa MC, Kholodenko BN, Taylor CT, Cheong A. A dynamic model of the hypoxia-inducible factor 1 (HIF-1) network. J Cell Sci 126. 1454-1463, 2013.
84. Nural-Guvener HF, Zakharova L, Nimlos J, Popovic S, Mastroeni D, Gaballa MA. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90 cardiac myofibroblast activation. Fibrogenesis Tissue Rep 7. 10-10, 2014.
85. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 105. S13-S33, 2011.
86. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci 13, 2008.
87. Oberyszyn TM. Inflammation and wound healing. Front Biosci 12. 2993-2999, 2007.
88. Oliver KM, Taylor CT, Cummins EP. Hypoxia regulation of NFB signalling during inflammation. the role of hydroxylases. Arthritis Res Ther 11. 215, 2009.
89. Pakyari M, Farrokhi A, Maharlooei M, Ghahary A. Critical role of transforming growth factor beta in different phases of wound healing. Adv Wound Care 2. 215-224, 2013.
90. Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M. Transforming growth factor-β receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 282. 10405–10413, 2007.
91. Pinzani M, Rombouts K. Liver fibrosis. from the bench to clinical targets. Dig Liver Dis 36. 231–242, 2004.
92. Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep 63. 629–642, 2011.
93. Raghow R. The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J 8. 823–831, 1994.
94. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, Investigators IT. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370. 2071–2082, 2014.
95. Rieder F, Brenmoehl J, Leeb S, Schoelmerich J, Rogler G. Healing and fibrosis in intestinal disease. Gut 56. 130–139, 2007.
96. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134. 145–155, 2008.
97. Rutgeerts P, Vermiere S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 136. 1844–1844, 2009.
98. Ruthenborg RJ, Ban JJ, Wazir A, Takeda1 N, Kim JW. Regulation of Wound Healing and Fibrosis by Hypoxia and Hypoxia-Inducible Factor-1. Mol Cells 37. 637–643, 2014.
99. Samarakoon R, Overstreet JM, Higgins PJ. TGF- signaling in tissue fibrosis. Redox controls, target genes and therapeutic opportunities. Cell Signal 25. 264–268, 2013.
100. Sandborn WJ. Current directions in IBD therapy. what goals are feasible with biological modifiers? Gastroenterology 135. 1442–1447, 2008.
101. Scholz CC, Cavadas MAS, Tambuwala MM, Hams E, Rodriguez J, von Kriegsheim A, Cotter P, Bruning U, Fallon PG, Cheong A, Cummins EP, Taylor CT. Regulation of IL-1β-induced NF-kappa B by hydroxylases links key hypoxic and inflammatory signaling pathways. Proc Natl Acad Sci USA 110. 18, 490-18, 2013.
102. Scholz CC, Taylor CT. Targeting the HIF pathway in inflammation and immunity. Curr Opin Pharmacol 13. 646–653, 2013.
103. Schreml S, Szeimies RM, Prantl L, Karrer S, Landthaler M, Babilas P. Oxygen in acute and chronic wound healing. Br J Dermatol 163. 257–268, 2010.
104. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis. Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134. 136–151, 2001.
105. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12. 5447-5454, 1992.
106. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology.Nature 510. 92–101, 2014.
107. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, RamachandraRao S, Xu R, Fervenza FC, Kopp JB. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22. 1144–1151, 2011.
108. Shi-wen X, Parapuram SK, Pala D, Chen Y, Carter DE, Eastwood M, Denton CP, Abraham DJ, Leask A. Requirement of transforming growth factor β-activated kinase 1 for transforming growth factor β-induced α-smooth muscle actin expression and extracellular matrix contraction in fibroblasts. Arthritis Rheum 60. 234–241, 2009.
109. Siamopoulos KC, Kalaitzidis RG. Inhibition of the renin-angiotensin system and chronic kidney disease. Int Urol Nephrol 40. 1015–1025, 2008.
110. Simmons JG, Pucilowska JB, Keku TO, Lund PK. IGF-I and TGFβ1 have distinct effects on phenotype and proliferation of intestinal fibroblasts. Am J Physiol Gastrointest Liver Physiol 283. G809–G818, 2002.
111. Song YR, You SJ, Lee YM, Chin HJ, Chae DW, Oh YK, Joo KW, Han JS, Na KY. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transpl 25. 77–85, 2010.
112. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, Carlson W, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, Zeisberg M, Kalluri R. Regarding the mechanism of action of a proposed peptide agonist of the bone morphogenetic protein receptor activin-like kinase 3. Reply. Nat Med 19. 810–811, 2013.
113. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, CarlsonWJr, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, Zeisberg M, Kalluri R. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 18. 396-U264, 2012.
114. Suzuki K, Sun X, Nagata M, Kawase T, Yamaguchi H, Sukumaran V, Kawauchi Y, Kawachi H, Nishino T, Watanabe K, Yoneyama H, Asakura H. Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium. Pathol Int 61. 228–238, 2011.
115. Tambuwala MM, Cummins EP, Lenihan CR, Kiss J, Stauch M, Scholz CC, Fraisl P, Lasitschka F, Mollenhauer M, Saunders SP, Maxwell PH, Carmeliet P, Fallon PG, Schneider M, Taylor CT. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139:2093–2101, 2010.
116. Tandara AA, Mustoe TA. Oxygen in wound healing—more than a nutrient. World J Surg 28. 294–300, 2004.
117. Taylor CT. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J 409. 19–26, 2008.
118. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med 85. 1295–1300, 2007.
119. Taylor CT, Cummins EP. The role of NF-[1]B in hypoxia-induced gene expression. Hypoxia and consequences from molecule to malady. Ann NY Acad Sci 1177. 178–184, 2009.
120. Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) α increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 280. 36,36-96, 2005.
121. Thompson-Chagoyan OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (IBD). Role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 24. 339–352, 2005.
122. Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 21. 623–629, 2009.
123. Uemura M, Swenson ES, Gaca MDA, Giordano FJ, Reiss M, Wells RG. Smad2 and smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell 16. 4214–4224, 2005.
124. Ueno M, Maeno T, Nomura M, Aoyagi-Ikeda K, Matsui H, Hara K, Tanaka T, Iso T, Suga T, Kurabayashi M. Hypoxia-inducible factor-1 alpha mediates TGF-β-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 300. L740–L752, 2011.
125. Velnar T, Bailey T, Smrkoli V. The wound-healing process. an overview of the cellular and molecular mechanisms. J Int Med Res 37. 1528–1542, 2009.
126. Walsh DW, Godson C, Brazil DP, Martin F. Extracellular BMPantagonist regulation in development and disease. tied up in knots. Trends Cell Biol 20. 244–256, 2010.
127. Wang S, de Caestecker M, Kopp J, Mitu G, LaPage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 17. 2504–2512, 2006.
128. Whitman M, Rosen V, Brivanlou AH, Groppe JC, Sebald W, Mueller T. Regarding the mechanism of action of a proposed peptide agonistof the bone morphogenetic protein receptor activin-like kinase 3. Nat Med 19. 809–810, 2013.
129. Wiercinska E, Wickert L, Denecke B, Said HM, Hamzavi J, Gressner AM, Thorikay M, ten Dijke P, Mertens PR, Breitkopf K, Dooley S. Id1 is a critical mediator in TGF-β-induced transdifferentiation of rat hepatic stellate cells. Hepatology 43. 1032–1041, 2006.
130. Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep 6. 16, 2014.
131. Woodcock HV, Molyneaux PL, Maher TM. Reducing lung function decline in patients with idiopathic pulmonary fibrosis. potential of nintedanib. Drug Design Dev Ther 7. 503–510, 2013.
132. Wynn TA, Barron L. Macrophages. master regulators of inflammation and fibrosis. Semin Liver Dis 30. 245–257, 2010.
133. Wynn TA, Ramalingam TR. Mechanisms of fibrosis. therapeutic translation for fibrotic disease. Nat Med 18. 1028–1040, 2012.
134. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448. 427–434, 2007.
135. Yanagita M, Okuda T, Endo S, Tanaka M, Takahashi K, Sugiyama F, Kunita S, Takahashi S, Fukatsu A, Yanagisawa M, Kita T, Sakurai T. Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J Clin Invest 116. 70–79, 2006.
136. Yang I, Schwartz D. Epigenetics of idiopathic pulmonary fibrosis. Transl Res In press.
137. Yi JY, Shin I, Arteaga CL. Type I transforming growth factor-β receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem 280. 10,870-10,876, 2005.
138. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-β. J Biochem 147. 781–792, 2010.
139. Yu X, Fang Y, Ding X, Liu H, Zhu J, Zou J, Xu X, Zhong Y. Transient hypoxia-inducible factor activation in rat renal ablation and reduced fibrosis with L-mimosine. Nephrology 17. 58–67, 2012.
140. Zepeda AB, Pessoa A Jr, Castillo RL, Figueroa CA, Pulgar VM, Farias JG. Cellular and molecular mechanisms in the hypoxic tissue. role of HIF-1 and ROS. Cell Biochem Funct 31. 451–459, 2013.
141. Zhang P, Cai Y, Soofi A, Dressler GR. Activation of Wnt11 by transforming growth factor-β drives mesenchymal gene expression through non-canonical Wnt protein signaling in renal epithelial cells. J Biol Chem 287. 21290–21302, 2012.
142. Zhang Q, Shi Y, Wada J, Malakauskas SM, Liu M, Ren Y, Du C, Duan H, Li Y, Li Y, Zhang Y. In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. Plos One 5, 2010.
143. Zhao H, Dong Y, Tian X, Tan TK, Liu Z, Zhao Y, Zhang Y, Harris DC, Zheng G. Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. World J Nephrol 2. 84–89, 2013.
144. Zhao JS, Shi W, Wang YL, Chen H, Bringas P, Datto MB, Frederick JP, Wang XF, Warburton D. Smad3 deficiency attenuates bleomycininduced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 282. L585–L593, 2002.
145. Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM, Wei X, Chen X, Chen Z, Beres JM, Zhang J, Tsao JL, Brenner MC, Zhang Y, Fan C, DePinho RA, Paik J, Gygi SP, Kaelin WG Jr, Zhang Q. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev 28. 1429–1444, 2014.
146. Zhou Q, Pardo A, Koenigshoff M, Eickelberg O, Budinger GRS, Thavarajah K, Gottardi CJ, Jones J, Varga J, Selman M, Sznajder JI, Raj JU, Zhou G. Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis. FASEB J 25. 3032–3044, 2011.